Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Liberal withdrawal of accelerated approvals will have negative ramifications for oncology patients, says GlobalData

The Food and Drug Administration’s (FDA) accelerated approval program has recently come under fire due to high-profile withdrawals of immune checkpoint inhibitors (ICIs) from the oncology market. Conservative withdrawal of drugs marketed under accelerated approval has more upside for cancer patients with few available options compared to liberal withdrawal, says GlobalData, a leading data and […]
Read more

UK COVID-19 vaccine approvals would have taken longer if UK remained in EU, say European healthcare professionals in a GlobalData survey

More than 50% of surveyed healthcare industry professionals from Europe believe that Brexit allowed the UK to accelerate its COVID-19 vaccines approval process 31% of respondents from the UK highlighted that the UK’s departure from the bloc did not influence the fast-tracked authorization of COVID-19 vaccines While the Pfizer/BioNTech vaccine approval was commenced in accordance with […]
Read more

Roche’s antibody cocktail for COVID-19 may face affordability issues in India, says GlobalData

Following the news that Roche has received emergency use authorization (EUA) for a COVID-19 antibody cocktail casirivimab and imdevimab; Prashant Khadayate, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “Roche’s antibody cocktail casirivimab and imdevimab are among the only two drugs to be exclusively developed and approved for COVID-19 treatment. […]
Read more

Merck & Co and BMS set to retain their positions as current and future key players in head and neck cancer, says GlobalData

Merck & Co. and Bristol-Myers Squibb (BMS) have transformed the treatment paradigm in advanced and metastatic head and neck squamous cell carcinoma (HNSCC) settings by improving real-world patient outcomes in the first and second-line metastatic setting. These two companies are expected to retain their position as market leaders in HNSCC, primarily based on proven product […]
Read more

Hepatocellular carcinoma market to reach $5.3bn by 2029, says GlobalData

The hepatocellular carcinoma (HCC) market is expected to grow from $1bn in 2019 to $5.3bn in 2029 in the eight major markets (8MM*) at a compound annual growth rate (CAGR) of 17.8%, says GlobalData, a leading data and analytics company. The company’s latest report, ‘Hepatocellular Carcinoma: Global Drug Forecast and Market Analysis to 2029’, reveals […]
Read more

Results from post hoc study may bolster current use of Veltassa among older patients with CKD-HK, says GlobalData

A post hoc analysis of the multicenter AMETHYST-DN study found that the use of Vifor Pharma’s Veltassa (patiromer) significantly reduced serum potassium in patients ages 75 years and older with chronic kidney disease (CKD)-related hyperkalemia (HK). This study could be of high clinical value to physicians with elderly patients looking to find an optimal treatment […]
Read more

Unmet needs in T1D highlight significant market gaps despite robust pipeline, according to GlobalData

It is expected that 15 therapeutics will launch in the Type 1 Diabetes (T1D) market in the eight major markets (8MM*) before 2030. They include Adocia’s BioChaperone Insulin lispro, an ultra-fast prandial insulin; Zealand Pharma’s dasiglucagon, a liquid-stable glucagon to manage hypoglycemia for use in a bihormonal pump; and Provention Bio’s teplizumab, the first preventative […]
Read more

NIH grant-funded drugs are being repurposed for COVID-19, says GlobalData

Drugs being developed for COVID-19 were awarded the highest number of SBIR/STTR funding grants, at 187 grants. Most grants awarded to drugs that are currently indicated for COVID-19 were awarded pre-2020, before the pandemic began, says GlobalData, a leading data and analytics company. Madeleine Roche MSc, Analyst at GlobalData comments: “It is likely that many […]
Read more

Freeline Therapeutics edges ahead of gene therapy competitors by progressing dose escalation for FLT190 Phase I/II study, says GlobalData

Freeline Therapeutics recently announced plans to progress dose escalation for its Phase I/II trial for FLT190, an adeno-associated variant (AAV) based gene therapy for Fabry disease. The current position that Freeline has achieved with FLT190 places the company ahead of its direct competitors and into a strategic position to dominate the Fabry gene therapy landscape, […]
Read more

China focuses on next-generation intranasal COVID-19 vaccines amid rising mutant strains, says GlobalData

COVID-19 infections continue to rise with several countries facing second-and third-wave infections with the newly evolved mutant strains, thereby increasing the demand for effective vaccines. Several pharmaceutical companies across the world have started working on the inhaled vaccine formulations and China is also developing next generation intranasal COVID-19 vaccines, says GlobalData, a leading data and […]
Read more

First cell therapy for solid tumors could be approved by 2022, says GlobalData

Although cell therapies such as CAR-T have been approved and used successfully to treat hematological cancers, there are currently no cell therapies approved for the treatment of solid tumors. However, positive data recently presented by Iovance Biotherapeutics from its lead candidate, tumor infiltrating lymphocyte (TIL) therapy lifileucel, in heavily pre-treated melanoma patients suggests an approval […]
Read more

CMOs reap the benefits of COVID-19 manufacturing and timescale demands, says GlobalData

The COVID-19 pandemic brought not just a more difficult business environment to operate in, but also opportunities for contract manufacturing organizations (CMOs), as even the largest biopharma companies require extra capacity to supply billions of doses. Due to compressed timelines and manufacturing scale challenges for COVID-19 vaccines and medicines, CMOs signed contract manufacturing service agreements […]
Read more

CureVac’s unique vaccine properties are key for mRNA vaccine delivery to developing nations, says GlobalData

As COVID-19 cases continue to soar in some countries, demand for Pfizer and Moderna’s vaccines is fast exceeding production capabilities, while restrictions placed on AstraZeneca and Johnson & Johnson’s adenovirus-based vaccines have placed additional pressures on global vaccine rollouts, particularly in Europe. CureVac’s expected entry into the COVID-19 vaccine market may provide a viable alternative […]
Read more
1 … 63 64 65 66 67 … 108